Boston Scientific announced a $14.5 billion cash-and-stock deal to acquire Penumbra, expanding its portfolio into mechanical thrombectomy, embolization and neurovascular devices. The transaction combines Boston Scientific’s global commercial reach with Penumbra’s devices—such as Lightning Bolt and Lightning Flash—that treat arterial, venous and pulmonary clots and neurovascular indications. Management highlighted strong recent revenue growth at Penumbra and said the deal is financed with cash and new debt to support an $11 billion cash component. The acquisition aims to accelerate access to minimally invasive clot-removal and embolization technologies across markets.